Utility of Contact Investigation of Drug Susceptible and Resistant TB in Tanzani

坦桑尼亚药物敏感和耐药结核病接触者调查的效用

基本信息

批准号：
7737108
负责人：
Elizabeth Fair
金额：
$ 12.42万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-18 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7737108
关键词：
Address Africa Africa South of the Sahara Applications Grants Area Budgets California Capital Caring Cause of Death Cities Clinical Research Cohort Studies Communities Cost Effectiveness Analysis Cost Measures Country Critical Care Data Detection Developed Countries Developing Countries Development Plans Disease Disease Outbreaks Drug Resistant Tuberculosis Drug resistance Drug-sensitive Early Diagnosis Early identification Economics Emergency Situation Enrollment Epidemic Epidemiologist Evaluation Extreme drug resistant tuberculosis Family Foundations Funding Future Genotype Goals Gold HIV HIV Infections Health Personnel High Prevalence Household Incidence Incidental Findings Infection Institutes International Interruption Intervention Investigation Isoniazid resistance Knowledge Laboratories Laboratory Research Learning Leprosy Life Low income Lung Measures Medical Research Medicine Mentored Research Scientist Development Award Mentors Methods Mutation Mycobacterium tuberculosis Organism Participant Pathogenicity Patient Education Patients Pattern Persons Pharmaceutical Preparations Policy Developments Predisposition Prevalence Preventive Intervention Principal Investigator Process Public Health Publishing Pulmonary Tuberculosis Relapse Research Research Personnel Research Technics Resistance Resources Restriction fragment length polymorphism Retreatment San Francisco Science Screening procedure Source Speed Sputum Tanzania Testing Time Training Treatment Failure Tuberculosis Universities Work World Health Organization authority base career career development case finding cost cost effectiveness design diagnosis standard disability disease transmission disorder control evidence base high risk indexing innovation isoniazid mathematical model novel strategies programs prospective public health emergency resistant strain therapy design transmission process tuberculosis treatment

项目摘要

DESCRIPTION (provided by applicant): This is an application for a K01 award for Dr. Elizabeth Fair, an epidemiologist in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco. Dr. Fair is establishing herself as an investigator in epidemiologic and cost effectiveness analyses to evaluate the feasibility, cost, and impact of new tuberculosis (TB) case detection methods in resource limited-settings with high incidences of TB and HIV and increasing threats of drug-resistant TB. This K01 award will provide Dr. Fair with the support necessary to accomplish the following goals: (1) to become expert in applying advanced analytic methods for evaluating the cost effectiveness of programmatic TB interventions; (2) to learn to apply mathematical modeling of infectious disease transmission for evaluating the impact of TB interventions; (3) to become expert in the design, enrollment, and management of a prospective cohort study in a low-resource setting; (4) to apply laboratory research techniques for TB genotyping and drug resistance testing; and (5) to develop and independent clinical research career. To achieve these goals, Dr. Fair has assembled a mentoring team comprised of a primary mentor, Dr. Philip Hopewell, an internationally recognized authority on global TB control, and 2 co-mentors: Dr. James G. Kahn, an internationally recognized expert on cost effectiveness studies, and Dr. Travis Porco, a well-published mathematical modeler and epidemiologist. Low case finding of new TB patients is a major limitation to global control of the disease, especially in high HIV-prevalence areas. Dr. Fair's research will determine whether household contact investigation in a low-income, high TB burden setting results in earlier diagnosis of TB (Aim 1). She will also assess the costs, cost-effectiveness, and impact of contact investigation under program conditions (Aim 2); and characterize the transmissibility and pathogenicity of M.tb strains from new cases found through household contact investigation (Aim 3). The research will form the basis for a future R01 grant application to address the scientific basis of TB transmission and pathogenicity, specifically of drug-resistant M.tb strains.

描述（由申请人提供）：这是伊丽莎白·费尔博士 (Elizabeth Fair) 的 K01 奖项申请，她是加州大学旧金山分校肺科和重症监护医学部的流行病学家。 Fair 博士正在将自己定位为流行病学和成本效益分析的调查员，以评估在资源有限、结核病和艾滋病毒高发以及毒品威胁日益增加的环境中新结核病 (TB) 病例检测方法的可行性、成本和影响耐药结核病。该 K01 奖项将为 Fair 博士提供实现以下目标所需的支持：(1) 成为应用先进分析方法评估规划性结核病干预措施成本效益的专家；（2）学会应用传染病传播的数学模型来评估结核病干预措施的影响； (3) 成为资源匮乏环境下前瞻性队列研究的设计、招募和管理方面的专家；（四）应用实验室研究技术进行结核病基因分型和耐药性检测； (5)发展并独立的临床研究事业。为了实现这些目标，Fair 博士组建了一个指导团队，其中包括一位主要导师 Philip Hopewell 博士（国际公认的全球结核病控制权威）和 2 位联合导师：James G. Kahn 博士（国际公认的专家）成本效益研究，以及 Travis Porco 博士，一位发表了大量文章的数学建模师和流行病学家。新结核病患者的低病例发现是全球控制该疾病的主要限制，特别是在艾滋病毒高流行地区。 Fair 博士的研究将确定在低收入、高结核病负担环境中进行家庭接触调查是否会导致结核病的早期诊断（目标 1）。她还将评估项目条件下接触者调查的成本、成本效益和影响（目标 2）；并描述通过家庭接触调查发现的新病例中结核分枝杆菌菌株的传播性和致病性（目标 3）。该研究将为未来的 R01 拨款申请奠定基础，以解决结核病传播和致病性的科学依据，特别是耐药结核病菌株的传播和致病性。